Bone marrow mesenchymal stem cells (BMSCs) represent an important source of cells for tissue repair. The tropism of these cells to the sites of injury and tumors has been well established. Their tumor-homing properties make BMSCs good candidates as antitumor agent delivery vehicles. In this study, we showed that BMSCs have the ability to migrate toward various cancer cells, including prostate cancer cells in vitro and in vivo and incorporating into the tumor mass. When infected with herpes simplex virus thymidine kinase (TK) gene by lentiviral transduction, TK-BMSCs maintained their tumor tropism capabilities and significantly inhibited the growth of subcutaneous PC3 prostate cancer xenografts in nude mice, in the presence of prodrug ganciclovir (GCV). Xenogenic TK-BMSCs also survived and exerted a significant antitumor effect in an animal model bearing metastastic RIF-1 (fibrosarcoma) tumor in the presence of prodrug GCV. The present study demonstrated that overexpression of TK in BMSCs did not affect their multidifferentiation potentials and their specific homing capacities toward the tumor mass, and the TK-BMSCs alone did not cause any harmful side effects in vivo. The use of TK-BMSCs as tumor-specific delivery vehicles together with controlled prodrug treatment may be a safe and novel anticancer therapy approach.
Get full access to this article
View all access options for this article.
References
1.
AboodyK.S., BushR.A., GarciaE.et al.2006. Development of a tumor-selective approach to treat metastatic cancer. PloS One, 1:e23.
2.
BarbashI.M., ChouraquiP., BaronJ.et al.2003. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium—feasibility, cell migration, and body distribution. Circulation, 108:863–868.
ChenX., XuH., WanC.et al.2006b. Bioreactor expansion of human adult bone marrow-derived mesenchymal stem cells. Stem Cells, 24:2052–2059.
8.
ChenX., McClurgA., ZhouG.Q.et al.2007. Chondrogenic differentiation alters the immunosuppressive property of bone marrow-derived mesenchymal stem cells, and the effect is partially due to the upregulated expression of B7 molecules. Stem Cells, 25:364–370.
9.
Croitoru-LamouryJ., LamouryF.M.J., ZaundersJ.J.et al.2007. Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone. J. Interferon Cytokine Res., 27:53–64.
10.
Di NicolaM., Carlo-StellaC., MagniM.et al.2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99:3838–3843.
11.
DvorakH.F.1986. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound-healing. N. Engl. J. Med., 315:1650–1659.
12.
DwyerR.M., Potter-BeirneS.M., HarringtonK.A.et al.2007. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin. Cancer Res., 13:5020–5027.
13.
ElzaoukL., MoellingK., PavlovicJ.2006. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp. Dermatol., 15:865–874.
14.
FillatC., CarrióM., CascanteA., SangroB.2003. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr. Gene Ther., 3:13–26.
15.
HakkarainenT., SärkiojaM., LehenkariP.et al.2007. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum. Gene Ther., 18:627–641.
16.
HallB., DembinskiJ., SasserA.K.et al.2007. Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int. J. Hematol., 86:8–16.
17.
HonczarenkoM., LeY., SwierkowskiM.et al.2006. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells, 24:1030–1041.
18.
IlsleyD.D., LeeS.H., MillerW.H., KuchtaR.D.1995. Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. Biochemistry, 34:2504–2510.
19.
KawadaH., FujitaJ., KinjoK.et al.2004. Non-hematopoietic bone marrow cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction: Possible contribution of mesenchymal stem cells. Blood, 104:3581–3587.
20.
KhakooA.Y., PatiS., AndersonS.A.et al.2006. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med., 203:1235–1247.
21.
KucerovaL., AltanerovaV., MatuskovaM.et al.2007. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res., 67:6304–6313.
22.
LoveZ., WangF., DennisJ.et al.2007. Imaging of mesenchymal stem cell transplant by bioluminescence and PET. J. Nucl. Med., 48:2011–2020.
23.
LuY.R., YuanY., WangX.J.et al.2008. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol. Ther., 7:245–251.
24.
MariniF., StudenyM., AndreeffM.2005. Re: Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents response. J. Natl. Cancer Inst., 97:541–542.
25.
MenonL.G., PicinichS., KoneruR.et al.2007. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells, 25:520–528.
26.
MileticH., FischerY., LitwakS.et al.2007. Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol. Ther., 15:1373–1381.
27.
MishraP.J., MishraP.J., HumeniukR.et al.2008. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res., 68:4331–4339.
28.
NakamizoA., MariniF., AmanoT.et al.2005. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res., 65:3307–3318.
29.
O'DonoghueK., ChoolaniM., ChanJ.et al.2003. Identification of fetal mesenchymal stem cells in maternal blood: implications for non-invasive prenatal diagnosis. Mol. Hum. Reprod., 9:497–502.
30.
PotianJ.A., AvivH., PonzioN.M.et al.2003. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol., 171:3426–3434.
31.
RayP., TsienR., GambhirS.S.2007. Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. Cancer Res., 67:3085–3093.
32.
RingeJ., StrassburgS., NeumannK.et al.2007. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J. Cell. Biochem., 101:135–146.
33.
SasakiM., AbeR., FujitaY.et al.2008. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J. Immunol., 180:2581–2587.
34.
SatakeK., LouJ., LenkeL.G.2004. Migration of mesenchymal stem cells through cerebrospinal fluid into injured spinal cord tissue. Spine, 29:1971–1979.
35.
ShiM., LiJ., LiaoL.et al.2007. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica, 92:897–904.
36.
SonB.R., Marquez-CurtisL.A., KuciaM.et al.2006. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells, 24:1254–1264.
37.
SonabendA.M., UlasovI.V., TylerM.A.et al.2008. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells, 26:831–841.
38.
Stoff-KhaliliM.A., RiveraA.A., MathisJ.M.et al.2007. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res. Treat., 105:157–167.
39.
StudenyM., MariniF.C., ChamplinR.E.et al.2002. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res., 62:3603–3608.
40.
StudenyM., MariniF.C., DembinskiJ.L.et al.2004. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst., 96:1593–1603.
41.
TseW.T., PendletonJ.D., BeyerW.M.et al.2003. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation, 75:389–397.
42.
Von LuttichauI., NotohamiprodjoM., WechselbergerA.et al.2005. Human adult CD34(–) progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev., 14:329–336.
43.
WangY., ChenX., ArmstrongM.A., LiG.2007. Survival of bone marrow-derived mesenchymal stem cells in a xenotransplantation model. J. Orthop. Res., 25:926–932.
44.
WellsC.M., RidleyA.J.2005. Analysis of cell migration using the Dunn chemotaxis chamber and time-lapse microscopy. Methods Mol. Biol., 294:31–41.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
